香港股市 已收市

貝康醫療-B (2170.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
11.740+0.160 (+1.38%)
收市價: 03:58PM HKT

貝康醫療-B

A3 Biobay Building
Unit 101 No. 218 Xinghu Street Suzhou Industrial Park
Suzhou 215000
China
86 40 0188 7878
http://www.basecare.cn

版塊Healthcare
行業Medical Devices
全職員工229

高階主管

名稱標題支付行使價出生年份
Dr. Bo Liang Ph.D.Chairman & GM1981
Ms. Jing DaiCFO & Joint Company Sec.1988
Mr. Maoshe RuiCOO & Exec. Director1989
Mr. Lingyin KongCTO & Exec. Director1981
Mr. Lok Kwan Yim A.C.I.S., A.C.S.Joint Company Sec.1988
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, and NGS sequencer. It also distributes DA8600 kits, which is designed for clinical applications in various genetic research and services; and engages in the research, development, manufacture, and sale of medical devices and instruments. It serves to hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.

公司管治

截至 無 止,貝康醫療-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。